Top

Published in:

01-04-2016 | Original Article

Dysgeusia and weight loss under treatment with vismodegib: benefit of nutritional management

Authors: Marie Le Moigne, Mélanie Saint-Jean, Adam Jirka, Gaëlle Quéreux, Lucie Peuvrel, Anabelle Brocard, Aurélie Gaultier, Amir Khammari, Dominique Darmaun, Brigitte Dréno

Published in: Supportive Care in Cancer | Issue 4/2016

Abstract

Purpose

Whereas vismodegib is effective in the treatment of locally advanced/metastatic basal cell carcinoma, dysgeusia and weight loss are common side effects of such treatment. The main objective of this study was to monitor the nutritional status of vismodegib-treated patients. Secondary objective was to assess the incidence of dysgeusia and the benefit of early nutritional management.

Methods

This prospective study included all patients who started vismodegib between October 2011 and May 2013 at Nantes University Hospital. Prior to July 2012, patients treated with vismodegib had not received any specific nutritional management (Historical cohort). Body weight and presence of dysgeusia were recorded monthly. Patients treated after July 2012 (Nutrition cohort) were evaluated by a physician of the Nutrition Support Unit and received dietary counseling at vismodegib initiation. A standardized nutritional management protocol was initiated in case of significant weight loss.

Results

Forty-five patients (21 and 24 in the Nutrition and Historical cohort, respectively) were enrolled. In the Nutrition cohort, five patients (24 %) were undernourished at vismodegib initiation, and the 6-month cumulative incidence of dysgeusia was 71 %. Eight patients (38 %) and 13 patients (54 %) had a weight loss greater than 5 % in the Nutrition and Historical cohort, respectively (p = 0.3727).

Conclusion

The results of this pilot study suggest the benefit of early nutritional screening. The potential benefit of nutritional support in this setting warrants further investigation.

Xie J, Murone M, Luoh SM et al (1998) Activating smoothened mutations in sporadic basal-cell carcinoma. Nature 391:90–92. doi:10.1038/34201 CrossRefPubMed

Sekulic A, Migden MR, Oro AE et al (2012) Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 366:2171–2179. doi:10.1056/NEJMoa1113713 CrossRefPubMed

Tang JY, Mackay-Wiggan JM, Aszterbaum M et al (2012) Inhibiting the Hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 366:2180–2188. doi:10.1056/NEJMoa1113538 PubMedCentralCrossRefPubMed

Chang ALS, Solomon JA, Hainsworth JD et al (2014) Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol 70:60–69. doi:10.1016/j.jaad.2013.09.012 CrossRefPubMed

Basset-Seguin N, Hauschild A, Grob J-J et al (2015) Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol. doi:10.1016/S1470-2045(15)70198-1 PubMed

Baker JP, Detsky AS, Wesson DE et al (1982) Nutritional assessment: a comparison of clinical judgement and objective measurements. N Engl J Med 306:969–972. doi:10.1056/NEJM198204223061606 CrossRefPubMed

Guigoz Y, Vellas BJ (1997) Malnutrition in the elderly: the Mini Nutritional Assessment (MNA). Ther Umsch Rev Thérapeutique 54:345–350

Thibault R, Goujon N, Le Gallic E et al (2009) Use of 10-point analogue scales to estimate dietary intake: a prospective study in patients nutritionally at-risk. Clin Nutr 28:134–140. doi:10.1016/j.clnu.2009.01.003 CrossRefPubMed

Chren M-M (2012) The Skindex instruments to measure the effects of skin disease on quality of life. Dermatol Clin 30:231–236. doi:10.1016/j.det.2011.11.003 PubMedCentralCrossRefPubMed

10.

Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376CrossRefPubMed

11.

National Cancer Institute. Common terminology criteria for adverse events v4.0, NCI, NIH, DHHS. May 29, 2009. NIH publication # 09-7473

12.

Schroll M, Jørgensen L, Osler M, Davidsen M (1993) Chronic undernutrition and the aged. Proc Nutr Soc 52:29–37CrossRefPubMed

13.

Abbasi AA, Rudman D (1994) Undernutrition in the nursing home: prevalence, consequences, causes and prevention. Nutr Rev 52:113–122CrossRefPubMed

14.

Sánchez-Lara K, Sosa-Sánchez R, Green-Renner D et al (2010) Influence of taste disorders on dietary behaviors in cancer patients under chemotherapy. Nutr J 9:15. doi:10.1186/1475-2891-9-15 PubMedCentralCrossRefPubMed

15.

Yang H, Cong W-N, Yoon JS, Egan JM (2015) Vismodegib, an antagonist of Hedgehog signaling, directly alters taste molecular signaling in taste buds. Cancer Med 4:245–252. doi:10.1002/cam4.350 PubMedCentralCrossRefPubMed

16.

Berteretche MV, Dalix AM, d’ Ornano AMC et al (2004) Decreased taste sensitivity in cancer patients under chemotherapy. Support Care Cancer 12:571–576. doi:10.1007/s00520-004-0589-2 CrossRefPubMed

17.

Heckmann SM, Hujoel P, Habiger S et al (2005) Zinc gluconate in the treatment of dysgeusia—a randomized clinical trial. J Dent Res 84:35–38CrossRefPubMed

18.

Najafizade N, Hemati S, Gookizade A et al (2013) Preventive effects of zinc sulfate on taste alterations in patients under irradiation for head and neck cancers: a randomized placebo-controlled trial. J Res Med Sci 18:123–126PubMedCentralPubMed

19.

Hovan AJ, Williams PM, Stevenson-Moore P et al (2010) A systematic review of dysgeusia induced by cancer therapies. Support Care Cancer 18:1081–1087. doi:10.1007/s00520-010-0902-1 CrossRefPubMed

20.

Tupe RP, Chiplonkar SA (2009) Zinc supplementation improved cognitive performance and taste acuity in Indian adolescent girls. J Am Coll Nutr 28:388–396CrossRefPubMed

21.

Stewart-Knox BJ, Simpson EEA, Parr H et al (2008) Taste acuity in response to zinc supplementation in older Europeans. Br J Nutr 99:129–136. doi:10.1017/S0007114507781485 CrossRefPubMed

22.

Dummer R Basset-Seguin N, Hansson J, et al. Impact of treatment breaks on vismodegib patient outcomes: exploratory analysis of the STEVIE study. 2015 ASCO Annual Meeting. http://meetinglibrary.asco.org/content/144375-156. Accessed 28 Jul 2015.

Title: Dysgeusia and weight loss under treatment with vismodegib: benefit of nutritional management
Authors: Marie Le Moigne
Mélanie Saint-Jean
Adam Jirka
Gaëlle Quéreux
Lucie Peuvrel
Anabelle Brocard
Aurélie Gaultier
Amir Khammari
Dominique Darmaun
Brigitte Dréno
Publication date: 01-04-2016
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 4/2016
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-015-2932-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2016

Revisiting classification of pain from bone metastases as mild, moderate, or severe based on correlation with function and quality of life

Integrative medicine, quality of life and gynecological cancer

Health-related quality of life of Chinese patients with prostate cancer in comparison to general population and other cancer populations

A randomised controlled trial comparing the effects of a 12-week supervised exercise versus usual care on outcomes in haematological cancer patients

Tight junction defects are seen in the buccal mucosa of patients receiving standard dose chemotherapy for cancer

Psychological distress, optimism and general health in breast cancer survivors: a data linkage study using the Scottish Health Survey

Keynote webinar | Spotlight on antibody–drug conjugates in cancer